Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03454451 · ClinicalTrials.gov registry record · Phase 1
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
A Phase 1 study, sponsored by Corvus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT03454451 is a Phase 1 study that has completed, run by Corvus Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT03454451, a Phase 1 study, has completed, sponsored by Corvus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.
Interventions
- DRUG CPI-006
- DRUG CPI-006 + ciforadenant
- DRUG CPI-006 + pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2023-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03454451
The ClinicalTrials.gov registry entry for NCT03454451 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corvus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CPI-006 is the first listed.
NCT03454451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03454451 about?
NCT03454451 is a clinical study titled "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers". This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (...
What is the current status of trial NCT03454451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2018-04-25. Estimated completion is 2023-02-19.
What interventions are being tested in trial NCT03454451?
The interventions under investigation include: CPI-006 (DRUG), CPI-006 + ciforadenant (DRUG), CPI-006 + pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03454451?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.